Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer.

Expert Opinion on Therapeutic Targets
John S P Yuen, Valentine M Macaulay

Abstract

The type 1 insulin-like growth factor receptor (IGF1R) plays a critical role in transformation, invasion and apoptosis protection, and is an attractive cancer treatment target. To review IGF1R antibodies and kinase inhibitors that are in preclinical and clinical development, and to discuss questions that will influence the success of this approach in clinical practice. This review is drawn from published literature, meeting abstracts and online resources. IGF1R blockade is generally well tolerated although it can induce hyperglycaemia. Single-agent activity has been documented in Ewing's sarcoma but not thus far in common solid tumours. Key issues include identification of factors that influence sensitivity to IGF1R blockade, and how most effectively to combine IGF1R inhibitors with other treatments.

References

Nov 1, 1989·The Journal of Clinical Investigation·C L ArteagaC K Osborne
Jan 1, 1985·Journal of Cell Science. Supplement·S P NissleyM M Rechler
Feb 6, 1985·Nature·M B Sporn, A B Roberts
Aug 27, 1993·Annals of the New York Academy of Sciences·F A McMorrisN Marchetti
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·C SellR Baserga
Dec 1, 1993·Genes & Development·L Powell-BraxtonT A Stewart
Dec 1, 1995·Molecular Reproduction and Development·R J Davis
Jul 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·P BurfeindJ Ilan
Jan 1, 1995·Antisense Research and Development·A M Krieg, C A Stein
Dec 1, 1996·Molecular Neurobiology·A J D'ErcoleG Gutierrez-Ospina
Jun 7, 1997·Biochimica Et Biophysica Acta·R BasergaB Valentinis
Jan 1, 1997·Neurobiology of Disease·E L FeldmanJ W Russell
Feb 20, 1999·The Journal of Biological Chemistry·C Arbet-EngelsW Eckhart
Mar 4, 2000·The Biochemical Journal·B Vanhaesebroeck, D R Alessi
May 12, 2000·Biochimica Et Biophysica Acta·S T Crooke
Jul 7, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M Pollak
Jul 27, 2000·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·K I Rother, D Accili
Aug 29, 2000·Cellular and Molecular Life Sciences : CMLS·T E AdamsC W Ward
Oct 18, 2000·Proceedings of the National Academy of Sciences of the United States of America·M P PlayfordV M Macaulay
May 2, 2001·Advances in Protein Chemistry·J W Park, J Smolen
Nov 6, 2001·Nature Structural Biology·S FavelyukisW T Miller

❮ Previous
Next ❯

Citations

May 17, 2011·Breast Cancer Research and Treatment·Rinat YerushalmiHagen Kennecke
Nov 27, 2008·Journal of Mammary Gland Biology and Neoplasia·Quanri Jin, Francisco J Esteva
May 2, 2009·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sonja E SteigenTorsten O Nielsen
Feb 25, 2010·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Kahina OussedikPaola B Arimondo
Oct 15, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sara A FlaniganStephen Leong
May 9, 2012·Molecular Cancer Therapeutics·Ramdev KonijetiWilliam J Aronson
Dec 3, 2010·The Journal of Clinical Investigation·Qianghua HuVicki Huff
Jan 7, 2010·BMC Medicine·Haim Werner, Ilan Bruchim
Jan 10, 2013·The Oncologist·Colin E ChampNicole L Simone
Oct 2, 2009·Future Oncology·Lloyd Balbuena, Alan G Casson
Feb 5, 2014·The Journal of Endocrinology·Gordon MoodyFrank J Calzone
Aug 29, 2013·International Journal of Endocrinology·Rosalyne L Westley, Felicity E B May
Jul 10, 2013·Journal of Pharmacological and Toxicological Methods·David A BrottJoAnne Saye
Aug 13, 2009·Expert Review of Anticancer Therapy·David M ThomasAlessandro Gronchi
Oct 18, 2008·Expert Review of Anticancer Therapy·Susan Ann Burchill
Jul 23, 2011·Expert Opinion on Investigational Drugs·Timothy A YapJohann S de Bono
Feb 24, 2010·Expert Opinion on Biological Therapy·Antonio Gualberto
May 4, 2012·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Benjamin W TurneyValentine M Macaulay
Oct 29, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Zohar Attias-GevaHaim Werner
Mar 19, 2011·Bioorganic & Medicinal Chemistry Letters·John L BuchananXiaotian Zhu
Jul 6, 2010·European Journal of Pharmacology·Anna BielawskaKrzysztof Bielawski
Feb 3, 2009·Current Opinion in Genetics & Development·Benjamin S Braun, Stephen L Lessnick
Oct 31, 2008·Best Practice & Research. Clinical Endocrinology & Metabolism·Michael Pollak
Jun 16, 2010·Chemical Biology & Drug Design·Conception NemecekDominique Lesuisse
Jul 18, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Li-Meng WangMing-Jie Xie
Jan 9, 2013·Expert Opinion on Therapeutic Targets·Ilan Bruchim, Haim Werner
May 28, 2013·Cell Cycle·Anthony D SalehNicole L Simone
Nov 28, 2012·The Lancet Oncology·Haim Werner, Ilan Bruchim
Aug 16, 2014·Cancer Treatment Reviews·Helen KingValentine M Macaulay
Apr 14, 2015·BioMed Research International·Varsha P BrahmkhatriHanudatta S Atreya

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis